Outcome evaluation for the treatment of low flow venous and lymphatic malformations

Abstract Purpose To propose a standardized method of subjectively and objectively evaluating outcomes of sclerotherapy in treating low flow vascular malformations. Materials and methods Sixty-six patients with low flow vascular malformations (venous, lymphatic, or combined) were treated with percuta...

Full description

Saved in:
Bibliographic Details
Main Authors: R. M. Moussa, A. O. Oseni, S. Patel, L. Mailli, R. Morgan, L. A. Ratnam
Format: Article
Language:English
Published: SpringerOpen 2024-11-01
Series:CVIR Endovascular
Subjects:
Online Access:https://doi.org/10.1186/s42155-024-00493-z
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850064435209568256
author R. M. Moussa
A. O. Oseni
S. Patel
L. Mailli
R. Morgan
L. A. Ratnam
author_facet R. M. Moussa
A. O. Oseni
S. Patel
L. Mailli
R. Morgan
L. A. Ratnam
author_sort R. M. Moussa
collection DOAJ
description Abstract Purpose To propose a standardized method of subjectively and objectively evaluating outcomes of sclerotherapy in treating low flow vascular malformations. Materials and methods Sixty-six patients with low flow vascular malformations (venous, lymphatic, or combined) were treated with percutaneous sclerotherapy using bleomycin, doxycycline, or sodium tetradecyl sulphate. Each lesion required between 2–5 sessions of sclerotherapy with 8-week intervals in between. The success of sclerotherapy was evaluated subjectively and objectively. The subjective response was based on the degree of patient satisfaction, by recording improvement of their symptoms and quality of life. The objective response was based on the changes in lesion characteristics after treatment, by recording changes in size, sonographic features, number of cystic spaces, and development of phleboliths. Results 91% of our patients were satisfied with the treatment and reported improvement of symptoms and quality of life. Radiologically, 62% (41/66) of the patients had a reduction in lesion size, 77% (51/66) had a change in echogenicity, 84% (51/61) had a reduction in cystic spaces, and 68% (30/44) developed phleboliths. Of the patients reporting significant improvement, 94% displayed reduction in cystic spaces, 89% displayed change in the echogenicity and 71% showed changes in the size of the lesions, representing a linear correlation. Conclusion Evaluating the outcomes of percutaneous sclerotherapy for treating vascular malformations is a recognized challenge. Creating a questionnaire with defined parameters to apply before and after treatment allows objective measurement of outcomes. This will enable improved treatment pathways and treatment choice for patients, informed consent, and enable outcome comparison with other centers.
format Article
id doaj-art-69a4e1c4e9fb4a89b9fe33058c4a4112
institution DOAJ
issn 2520-8934
language English
publishDate 2024-11-01
publisher SpringerOpen
record_format Article
series CVIR Endovascular
spelling doaj-art-69a4e1c4e9fb4a89b9fe33058c4a41122025-08-20T02:49:18ZengSpringerOpenCVIR Endovascular2520-89342024-11-017111210.1186/s42155-024-00493-zOutcome evaluation for the treatment of low flow venous and lymphatic malformationsR. M. Moussa0A. O. Oseni1S. Patel2L. Mailli3R. Morgan4L. A. Ratnam5George’s Healthcare NHS Trust, St George’s University Hospitals NHS Foundation TrustGeorge’s Healthcare NHS Trust, St George’s University Hospitals NHS Foundation TrustGeorge’s Healthcare NHS Trust, St George’s University Hospitals NHS Foundation TrustGeorge’s Healthcare NHS Trust, St George’s University Hospitals NHS Foundation TrustGeorge’s Healthcare NHS Trust, St George’s University Hospitals NHS Foundation TrustGeorge’s Healthcare NHS Trust, St George’s University Hospitals NHS Foundation TrustAbstract Purpose To propose a standardized method of subjectively and objectively evaluating outcomes of sclerotherapy in treating low flow vascular malformations. Materials and methods Sixty-six patients with low flow vascular malformations (venous, lymphatic, or combined) were treated with percutaneous sclerotherapy using bleomycin, doxycycline, or sodium tetradecyl sulphate. Each lesion required between 2–5 sessions of sclerotherapy with 8-week intervals in between. The success of sclerotherapy was evaluated subjectively and objectively. The subjective response was based on the degree of patient satisfaction, by recording improvement of their symptoms and quality of life. The objective response was based on the changes in lesion characteristics after treatment, by recording changes in size, sonographic features, number of cystic spaces, and development of phleboliths. Results 91% of our patients were satisfied with the treatment and reported improvement of symptoms and quality of life. Radiologically, 62% (41/66) of the patients had a reduction in lesion size, 77% (51/66) had a change in echogenicity, 84% (51/61) had a reduction in cystic spaces, and 68% (30/44) developed phleboliths. Of the patients reporting significant improvement, 94% displayed reduction in cystic spaces, 89% displayed change in the echogenicity and 71% showed changes in the size of the lesions, representing a linear correlation. Conclusion Evaluating the outcomes of percutaneous sclerotherapy for treating vascular malformations is a recognized challenge. Creating a questionnaire with defined parameters to apply before and after treatment allows objective measurement of outcomes. This will enable improved treatment pathways and treatment choice for patients, informed consent, and enable outcome comparison with other centers.https://doi.org/10.1186/s42155-024-00493-zLow flow venous and lymphatic malformationsVascular malformationSclerotherapy
spellingShingle R. M. Moussa
A. O. Oseni
S. Patel
L. Mailli
R. Morgan
L. A. Ratnam
Outcome evaluation for the treatment of low flow venous and lymphatic malformations
CVIR Endovascular
Low flow venous and lymphatic malformations
Vascular malformation
Sclerotherapy
title Outcome evaluation for the treatment of low flow venous and lymphatic malformations
title_full Outcome evaluation for the treatment of low flow venous and lymphatic malformations
title_fullStr Outcome evaluation for the treatment of low flow venous and lymphatic malformations
title_full_unstemmed Outcome evaluation for the treatment of low flow venous and lymphatic malformations
title_short Outcome evaluation for the treatment of low flow venous and lymphatic malformations
title_sort outcome evaluation for the treatment of low flow venous and lymphatic malformations
topic Low flow venous and lymphatic malformations
Vascular malformation
Sclerotherapy
url https://doi.org/10.1186/s42155-024-00493-z
work_keys_str_mv AT rmmoussa outcomeevaluationforthetreatmentoflowflowvenousandlymphaticmalformations
AT aooseni outcomeevaluationforthetreatmentoflowflowvenousandlymphaticmalformations
AT spatel outcomeevaluationforthetreatmentoflowflowvenousandlymphaticmalformations
AT lmailli outcomeevaluationforthetreatmentoflowflowvenousandlymphaticmalformations
AT rmorgan outcomeevaluationforthetreatmentoflowflowvenousandlymphaticmalformations
AT laratnam outcomeevaluationforthetreatmentoflowflowvenousandlymphaticmalformations